Morningstar Rating

Stock Research and Analysis

by Michael Waterhouse

Bulls Say

International expansion and complementary acquisitions should open new growth avenues for CareFusion.
CareFusion's high-priority devices and recurring consumables revenue help reduce the firm's exposure to hospital spending cycles.
Management's ongoing restructuring efforts should continue to drive dramatic improvements in profitability and returns on capital. Read more 

Bears Say

CareFusion's long-term growth potential could be dragged down by products that feature little innovation and the firm's minimal exposure to emerging markets.
Weak hospital spending will probably remain a modest growth headwind for CareFusion in the near term.
While recent acquisitions have complemented CareFusion's core operations and expanded its geographic footprint, CareFusion is likely to face difficulty expanding into product categories that it does not have expertise in. Read more 


We give CareFusion standard marks for shareholder stewardship. Because CareFusion as a stand-alone company is a newcomer to the public markets, we plan to monitor management's actions closely in the near future. So far, we think management's capital-allocation   Read more 


CareFusion has two operating segments: medical systems and procedural solutions. The medical systems segment manufactures and markets infusion pumps, medication dispensers,  Read more 

Health Care a Leader in Moat Stocks 
Watch more 

Premium Membership

View all of our analyst reports with a free trial to Premium.